TOP 10 Mama
  1. Início

Programação

Filtrar atividades
Auditório
08:25 - 08:30
Abertura

Abertura

Auditório
08:30 - 09:30
Palestra

Os “practice-changing”

08:30 - 08:40
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. DESTINY-Breast03
08:40 - 08:50
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. DESTINY-Breast04
08:50 - 09:00
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. RxPONDER
09:00 - 09:10
Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer. TROPICS-02 (JCO)
09:10 - 09:30
Discussão
Auditório
09:30 - 09:45
Intervalo

Intervalo

Auditório
09:45 - 10:35
Palestra

Consolidando conhecimento

09:45 - 09:55
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer (MNL-2 NEJM)
09:55 - 10:05
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
10:15 - 10:25
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
10:25 - 10:35
Discussão
Auditório
10:35 - 10:50
Intervalo

Intervalo

Auditório
10:50 - 11:30
Palestra

Novos caminhos

10:50 - 11:00
Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer JCO
11:00 - 11:10
Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (E2108) JCO
11:10 - 11:20
Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy
11:20 - 11:30
Discussão
Auditório
11:30 - 11:35
Encerramento

Encerramento